FLUENT Corp (CNTMF) Fair Value & Analysis
Healthcare · US · Market cap $15.3M
FLUENT Corp
CNTMF · US
Fair value as of: Jul 29, 2026
From 1 valuation models · updated 13 days ago
Fair value updated Jul 29, 2026, revised from $0.0223 to $0.0220 (−1.2%) since Jun 26, 2026. Share price +9.2% over the past month.
Below-average quality, and screening another 12% overvalued on our models.
What matters now
- Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
- Quality 20/100 (below-average quality) with low evidence: read the verdict with care.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 29, 2026.
How to read this chart
60‑month range $0.0200 – $1.15 · the $0.0250 price screens above the $0.0220 fair value. Dashed = 300-day average. As of Jul 29, 2026.
Analysis
FLUENT Corp (CNTMF) currently trades at $0.0250, while our model-based Fair Value estimate is $0.0220, implying the stock looks roughly 12.0% overvalued today. The Quality Score stands at 20/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: low).
Over the trailing twelve months, FLUENT Corp generated revenue of $81.7M at a net margin of -96.3%. Revenue declined 21.9% year over year. Net debt stands at $64.0M. Fundamentals as of Jul 29, 2026
The share trades about 72% below its 52-week high and 25% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -49% fair-value upside, at -12%, CNTMF screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 1 models by family
Notify me when CNTMF reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 29, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 20 · Market factors (momentum, volatility) 20
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
FLUENT Corp., through its subsidiaries, cultivates, manufactures, processes, distributes, and sells medical cannabis products for medical and adult-use in the United States. Its medical cannabis products are offered in oral drops, capsules, topicals, syringes, dried flower, pre-rolls, cartridges, concentrates, and edibles.
Full company description
FLUENT Corp., through its subsidiaries, cultivates, manufactures, processes, distributes, and sells medical cannabis products for medical and adult-use in the United States. Its medical cannabis products are offered in oral drops, capsules, topicals, syringes, dried flower, pre-rolls, cartridges, concentrates, and edibles. The company also sells various third-party branded medical cannabis products, as well as other accessories. It offers its products under the Bag-O, FLUENT, Hyer Kind, Knack, MOODS, and Wandr brands. The company was formerly known as Cansortium Inc. and changed its name to FLUENT Corp. in February 2025. FLUENT Corp. was founded in 2015 and is headquartered in Tampa, Florida.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
FLUENT Corp reported revenue of $86.7M in FY2025 versus $65.4M in FY2021, a compound +7.3%/yr. Reported net income was −$72.5M in FY2025.
CNTMF screens 12% overvalued. Compare with Jiangsu Hengrui Pharmaceuticals Co →
Peer Group
Drug Manufacturers - Specialty & Generic · 622 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Drug Manufacturers - Specialty & Generic median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
PAST 0: with negative equity (buybacks among others) return on equity is not meaningfully computable.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 29, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥53.19 | ¥25.94 | -51% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,933 | ₹989.50 | -49% |
| Divi's Laboratories Limited DIVISLAB | ₹7,316 | ₹1,943 | -73% |
| Torrent Pharmaceuticals Limited TORNTPHARM | ₹4,763 | ₹1,329 | -72% |
| PharmaEssentia Corporation 6446 | 1,285 TWD | 221.01 TWD | -83% |
| Cipla Limited CIPLA | ₹1,439 | ₹1,001 | -30% |
| Zydus Lifesciences Limited ZYDUSLIFE | ₹1,151 | ₹703.32 | -39% |
| Lupin Limited LUPIN | ₹2,443 | ₹2,477 | +1% |
| Mankind Pharma Limited MANKIND | ₹2,484 | ₹983.11 | -60% |
| Dr. Reddy's Laboratories Limited DRREDDY | ₹1,211 | ₹874.79 | -28% |
Compare FLUENT Corp with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is FLUENT Corp (CNTMF) overvalued or undervalued?
What is the fair value of CNTMF?
What is the quality score of CNTMF?
What is the revenue of FLUENT Corp (CNTMF)?
What is the net profit margin of CNTMF?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track FLUENT Corp and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.